In the News Press Releases In the News Media Contact November 21, 2024 Endeavor Doses First Subject in Phase IIb Trial of ENV-101 for IPF Treatment August 27, 2024 What Will it Take to Solve the Devastating Riddle of Idiopathic Pulmonary Fibrosis? June 7, 2024 Study: ENV-101 Improves IPF Lung Function, Reverses Fibrosis May 20, 2024 Taking on Pharma Giants, Endeavor Links IPF Drug to Improved Lung Function in Phase 2 April 26, 2024 John Hood on Endeavor’s $132.5M Series C and Hedgehog Inhibition for IPF April 24, 2024 Endeavor BioMedicines Snags $132M for Phase 2 Fibrosis Drug, ADC Candidate October 19, 2023 Hummingbird’s HER3-targeted ADC Entices Endeavor to Sign $430M Licensing Deal September 24, 2021 1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib January 7, 2021 Endeavor BioMedicines Raises $62 Million to Combat Pulmonary Disease January 7, 2021 Endeavor Launches with $62m and a Hedgehog Inhibitor from Lilly January 7, 2021 Serial Biotech Entrepreneur John Hood Raises $62 Million for Company Aimed at Deadly Lung Disease January 7, 2021 My Newest Puzzle, Endeavor BioMedicines, and the Chance to Reverse a Devastating Pulmonary Disease
